Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-8 of 8
Keywords: Human epidermal growth factor receptor 2
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Journal:
Oncology
Oncology (2023) 101 (12): 836–842.
Published Online: 31 August 2023
... tissue-agnostic drugs, and more are anticipated in the future. One promising candidate for a tissue-agnostic classification is the antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Currently, T-DXd is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive and HER2...
Journal Articles
Subject Area:
Oncology
Noriko Fujita, Yukie Enomoto, Keiko Inakami, Tetsu Yanagisawa, Chikage Iguchi, Toyokazu Aono, Takashi Nomura, Hitoshi Yamamoto, Tsutomu Kasugai, Eiichi Shiba
Journal:
Oncology
Oncology (2020) 98 (1): 35–41.
Published Online: 14 January 2020
...Noriko Fujita; Yukie Enomoto; Keiko Inakami; Tetsu Yanagisawa; Chikage Iguchi; Toyokazu Aono; Takashi Nomura; Hitoshi Yamamoto; Tsutomu Kasugai; Eiichi Shiba Background: It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should...
Journal Articles
Subject Area:
Oncology
Yasuyuki Kojima, Reiko Yoshie, Hisanori Kawamoto, Arata Shimo, Tomoko Uejima, Tsuguo Iwatani, Ai Motoyoshi, Yoshihide Kanemaki, Narikazu Boku, Koichiro Tsugawa
Journal:
Oncology
Oncology (2019) 96 (6): 309–317.
Published Online: 20 March 2019
...Yasuyuki Kojima; Reiko Yoshie; Hisanori Kawamoto; Arata Shimo; Tomoko Uejima; Tsuguo Iwatani; Ai Motoyoshi; Yoshihide Kanemaki; Narikazu Boku; Koichiro Tsugawa Background: In treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the efficacy of capecitabine...
Journal Articles
Subject Area:
Oncology
Eiji Oki, Shinji Okano, Hiroshi Saeki, Yuichiro Umemoto, Koji Teraishi, Yu Nakaji, Koji Ando, Yoko Zaitsu, Nami Yamashita, Masahiko Sugiyama, Yuichiro Nakashima, Kippei Ohgaki, Yoshinao Oda, Yoshihiko Maehara
Journal:
Oncology
Oncology (2017) 93 (6): 387–394.
Published Online: 15 September 2017
.... Immunohistochemistry was used to detect PD-L1. Human epidermal growth factor receptor 2 (HER2) expression and phosphatase and tensin homolog (PTEN) loss of heterozygosity were investigated in these patients. RNA interference was used to downregulate HER2 expression, and PD-L1 protein expression was assessed by flow...
Journal Articles
Subject Area:
Oncology
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura, Tsuyoshi Saito, Toshihiro Tanaka, Megumi Teraoka, Kazuo Shimada, Kazuhisa Katayama, Toshihiro Koga, Kaname Kurashita, Satoshi Hasegawa, Hidekazu Todoroki, Yuichiro Kai, Yasuyo Ohi, Satoshi Toyoshima, Nobuyuki Arima, Shoshu Mitsuyama, Kazuo Tamura
Journal:
Oncology
Oncology (2017) 93 (1): 51–61.
Published Online: 06 May 2017
... Mitsuyama; Kazuo Tamura Objective: The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and the treatment outcomes using lapatinib plus capecitabine (LC) and to evaluate the influence of the estrogen receptor (ER) status...
Journal Articles
Subject Area:
Oncology
Yeon Hee Park, Seock-Ah Im, Eun Yoon Cho, Joong Hyun Ahn, Sook Young Woo, Seonwoo Kim, Bhumsuk Keam, Jeong Eon Lee, Wonshik Han, Seok Jin Nam, In Ae Park, Dong-Young Noh, Jung Hyun Yang, Jin Seok Ahn, Young-Hyuck Im
Journal:
Oncology
Oncology (2014) 86 (5-6): 279–288.
Published Online: 04 June 2014
..., instructions or products referred to in the content or advertisements. Ki-67 CS-IHC4 Hormone receptor Human epidermal growth factor receptor 2 Nomogram Breast cancer is the most common cancer among women throughout the world. About 13 million women are diagnosed with breast cancer each year...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (2012) 84 (1): 43–56.
Published Online: 30 October 2012
...Patricia Mucci LoRusso Therapies directed at endocrine receptors and human epidermal growth factor receptor 2 are important treatment options for patients with breast cancer; however, drug resistance and subsequent disease progression in patients with advanced disease is inevitable. The mammalian...
Journal Articles
Subject Area:
Oncology
Jee Hyun Kong, Yeon Hee Park, Jung A. Kim, Jeong Hoon Kim, Jina Yun, Jong Mu Sun, Young Woong Won, Soohyeon Lee, Seung Tae Kim, Eun Yoon Cho, Jin Seok Ahn, Young-Hyuck Im
Journal:
Oncology
Oncology (2011) 81 (1): 55–62.
Published Online: 16 September 2011
... on the breast hormonal receptor (HR) and human epidermal growth factor receptor 2 (HER2) status at the time of skin metastasis. Methods: We retrospectively reviewed the patients’ medical records with radiologic imaging studies. Results: The numbers of patients of each subtype were as follows: HR positive (HR+ve...
